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Lung cancer is a leading cause of cancer-
related deaths worldwide (Jemal et al., 
2010). Therefore, it is not surprising that 
numerous expression profiling studies have 
been performed to predict prognosis and re-
sponse to therapy (Suzuki et al., 2011; 
Bhattacharjee et al., 2001; Wigle et al., 2002; 
Tomida et al., 2004; Roepman et al., 2009; 
Chen et al., 2007; Lohr et al., 2012; Larsen 
et al., 2007; Stewart et al., 2012; Lu et al., 
2006; Guo et al., 2008; Beer et al., 2002; Lee 
et al., 2008). However, it remains unknown 
whether the identified prognostic genes add 
additional prognostic information beyond the 
traditional clinical parameters (Subramanion 
and Simon, 2010). The prognostic influence 
of individual genes has also been critically 
discussed, since there is almost no overlap 
between the previously published gene sig-
natures (Botling et al., 2013). To validate the 
prognostic relevance of individual genes, 
Botling et al. (2013) recently introduced a 
novel single institute cohort (‘Uppsala co-
hort’) with gene array data from 196 non-
small cell lung cancer (NSCLC) patients. 
They hypothesized that the difficulty to con-
firm the prognostic role of individual genes 
may be due to the generally-applied sequen-
tial validation strategy, where genes identi-
fied in one study are tested for significance 
in separate subsequent studies (Botling et al., 
2013; Lohr et al., 2012, 2013). The size of 
the individual studies is usually small, which 
may contribute to the negative results. 
Therefore, Botling et al. (2013) used an al-
ternative approach - the novel ‘Uppsala co-
hort’ was used as a training set to screen for 
genes significantly associated with progno-
sis. The 450 probe sets were validated in five 
publicly-available lung cancer cohorts of 860 
additional patients (Botling et al., 2013). 
However, instead of using a sequential ap-
proach, the authors applied a meta-analysis 
strategy, where as an initial step the associa-
tion of individual genes was assessed sepa-
rately in each cohort. The next step involved 
calculating significance of all studies. This 
approach is superior to the conventional ‘se-
quential strategy’, because it combines the 
statistical power of several patient cohorts. 
Fourteen genes, which were found to be sig-
nificantly associated with survival in the 
Uppsala cohort, were further confirmed in 
the meta-analysis (Table 1). One of the iden-
tified genes, the adhesion molecule CADM1, 
was additionally validated using im-
munostaining (Botling et al., 2013). Valida-
tion of prognostic genes seems to be particu-
larly challenging in lung cancer. This obser-
vation differs from what has been observed 
in other tumor entities, such as e.g. breast 
cancer, where validation of prognostic signa-
tures appears more straightforward (e.g.: 
Schmidt et al., 2008, 2011, 2012; Hellwig et 
al., 2010; Brase et al., 2010; Chen et al., 
2012). Proliferation, estrogen receptor and 
immune cell-associated sets of genes have 
been identified and validated in breast cancer 
(review: Schmidt et al., 2009; Siggelkow et 
al., 2012); and redox factors (Cadenas et al., 
2010), anti-apoptotic signatures (Petry et al., 
2010),
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Table 1: Prognostic genes identified and validated in non-small cell lung cancer (from Botling et al., 
2013) 
 
 
 
mechanoactivity (Martin et al., 2012) and 
senescence (Cadenas et al., 2012) associated 
genes have also been confirmed. The diffi-
culty in validating prognostic genes in lung 
cancer may be due to the greater contribution 
of environmental factors rather than genetic 
predisposition to the etiology and progres-
sion of the disease (Micale et al., 2013; 
Remmer, 1987; von Stechow et al., 2013). 
However, the degree to which genetic varia-
bility and environmental exposure contribute 
to cancer risk is still undergoing investiga-
tion, and remains highly controversial (Bolt, 
2013; Schwender et al., 2012; Hammad et 
al., 2013; Selinski et al., 2011, 2012a, b, 
2013; Golka et al., 2012, 2011, 2009). 
In conclusion, the current study of 
Botling et al. (2013) further illustrates the 
importance of validating prognostic genes in 
cancer. The study also demonstrates that the 
concept of a training set followed by a meta-
analysis-based validation in independent co-
horts is superior to the conventional ap-
proach of sequential cohort by cohort valida-
tion.  
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